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Introduction: We investigated the efficacy and toxicity of
pembrolizumab in patients with mesothelioma from a real-
world Australian population. We aimed to determine clin-
ical factors and predictive biomarkers that could help select
patients who are likely to benefit from pembrolizumab.
Method: Patients with mesothelioma who were treated
with pembrolizumab as part of the Insurance and Care New
South Wales compensation scheme were included. Clinical
information was collected retrospectively. Tumor bio-
markers such as programmed death-ligand 1 (PD-L1),
BAP1, and CD3-positive (CD3þ) tumor-infiltrating lym-
phocytes (TILs) were examined using archival formalin-
fixed paraffin-embedded tumor samples.
Results: A total of 98 patients were included with a median
age of 70 years (range, 46–91 y); 92% were men; 76% had
epithelioid subtype; 21% had an Eastern Cooperative
Oncology Group (ECOG) performance status of 0. Pem-
brolizumab was used as second-line or subsequent-line
treatment in 94 patients and as first-line treatment in
four patients. The overall response rate was 18%, and the
disease control rate was 56%. The median progression-free
survival (PFS) was 4.8 months (95% confidence interval:
3.6–6.2), and the median overall survival (OS) was 9.5
months (95% confidence interval: 6.6–13.7). Immune-
related adverse events occurred in 27% of patients, of
which nine (9%) were of grade 3 or higher. In the multi-
variable analysis, factors independently associated with
longer PFS included baseline ECOG status of 0 (median PFS:
12 mo versus 4 mo, p < 0.01) and PD-L1 tumor proportion
score of greater than or equal to 1% (median PFS: 6 mo
versus 4 mo, p < 0.01). Baseline platelet count of less than
or equal to 400  109/liter was independently associated
with longer PFS and OS (median PFS: 6 mo versus 2 mo, p ¼
0.05; median OS: 10 mo versus 4 mo, p ¼ 0.01), whereas
lack of pretreatment dexamethasone was independently
associated with OS but not PFS (median OS: 10 mo versus 3
mo, p ¼ 0.01). The odds of response were higher for pa-
tients with baseline ECOG status of 0 (p ¼ 0.02) and withgreater than or equal to 5% CD3þ TILs in the tumor (p <
0.01). PD-L1 expression, BAP1 loss, and CD3þ TILs in the
stroma were not significantly associated with the overall
response rate.
Conclusions: Immunotherapy is a reasonable treatment
option for patients with mesothelioma. Our results are
comparable to other clinical trials investigating pem-
brolizumab in mesothelioma in terms of response. Good
performance status assessment remains the most robust
predictor for patient outcomes. CD3þ TILs in the tumor
may help select patients that are likely to respond to
pembrolizumab, whereas factors such as PD-L1 expression,
baseline platelet count, and lack of pretreatment dexa-
methasone may help predict survival outcomes from pem-
brolizumab treatment.
 2020 The Authors. Published by Elsevier Inc. on behalf of
the International Association for the Study of Lung Cancer.
This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Malignant mesothelioma, a fatal cancer of the meso-
thelium, continues to have one of the poorest survival
rates of any cancer, with a median overall survival (OS)
ranging from 6 months to 25 months1 and a 5-year
survival rate of between 4.7% and 6.1%.2 It is primar-
ily caused by exposure to asbestos.1 Australia has one of
the highest reported incidences, with around 700 to 800
patients diagnosed each year, of which 94% constitute
malignant pleural mesothelioma (MPM), and the
remaining 6% are mostly peritoneal mesothelioma.1,2
In MPM, the standard approved first-line treatment is
currently combination chemotherapy using pemetrexed
Table 1. Comparison of Currently Available Results From Studies Using PD-1 or PD-L1 Checkpoint Inhibitors in Mesothelioma
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PD-L1 2 54 0–1 50a NR NR 6.9 8/54 (15%)
MERIT28
JapicCTI-163247
Nivolumab PD-1 2 34 0–1 29 68 17.3 6.1 26/34 (76%)
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Nivolumab þ ipilimumab PD-1 þ
CTLA-4







2 40 0–1 28 65 16.6 8 7/40 (18%)
NivoMes12
NCT02497508





















Pembrolizumab PD-1 1b 25 0–1 20 72 18 5.4 5/25 (20%)
NCT0239937119 Pembrolizumab PD-1 2 65 0–1 19 66 11.5 4.5 12/65 (18%)
Metaxas et al. (2018)16 Pembrolizumab PD-1 RCS 93 0–1
(71%)
























Avelumab PD-L1 1b 53 0–1 9 58 10.7 4.1 5/53 (9%)
Current study Pembrolizumab PD-1 RCS 98 0–1
(78%)
18 56 9.5 4.8 9/98 (9%)
Note: aAccording to mRECIST.
Chemo, chemotherapy; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group
performance status; mOS, median overall survival; mPFS, median progression-free survival; mRECIST, modified Response Evaluation Criteria in Solid Tumors;
NR, not reported; ORR, overall response rate; PD-1, programmed cell death protein 1; PD-L1, programmed cell death-ligand 1; RCS, retrospective cohort
study; RCT, randomized controlled trial.
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survival time by approximately 3 months in phase 3
randomized controlled trial.3 The addition of bev-
acizumab, an antibody against VEGF, has also been re-
ported to modestly increase survival.4 However, survival
outcomes still remain poor, with a median progression-
free survival (PFS) ranging from only 6 to 9 months.3-5
There is currently no approved second-line treatment
for malignant mesothelioma; hence, an urgent need for
improved treatment options.6
Over the past decade, immunotherapy has emerged
as a promising treatment option for several cancers.7,8 In
MPM, up to 60% of patients express programmed death-
ligand 1 (PD-L1), an immune-suppressing receptor that
binds to the programmed cell death protein 1 (PD-1)
receptor on T-cells to suppress their tumor-killing
function.9,10 Hence, a number of clinical trials have
investigated the safety and efficacy of immunotherapies
that block the PD-1 or PD-L1 pathway as the first-line or
subsequent-line treatment for patients with MPM(Table 1).7,11 Although preliminary results, in general,
revealed good treatment tolerability, the overall
response rate (ORR) ranges only from 10% to 30%. This
suggests only a small proportion of patients may benefit
from this therapy and highlights the urgent need for
predictive biomarkers to select patients for immuno-
therapy.7,11-13 In this study, we investigated the efficacy
and toxicity of pembrolizumab, a PD-1 antibody, in pa-
tients with mesothelioma from a real-world Australian
population. We aimed to identify predictive clinical fac-
tors and the role of PD-L1 expression, BAP1 expression,
and tumor-infiltrating lymphocytes (TILs) as predictive
biomarkers from pembrolizumab treatment.
Materials and Methods
Study Patients
Pembrolizumab was provided to individual patients at
the request of their treating physician by the Insurance
and Care (iCare) Dust Diseases Authority of New South
Wales (NSW), which is a workers’ compensation scheme
4 Ahmadzada et al JTO Clinical and Research Reports Vol. 1 No. 4in NSW, Australia that funds access to treatment for pa-
tients with dust-related diseases. The eligibility criteria to
receive iCare compensation include individuals who
developed mesothelioma as a result of occupational
exposure to dust, such as asbestos, while employed in an
NSW workplace. Pembrolizumab was then given off-label
by the physicians to eligible patients who were deemed
suitable candidates for immunotherapy and who were
unable to access the treatment locally through a clinical
trial setting. There were no strict inclusion and exclusion
criteria set out for accessing pembrolizumab as part of
this compensation scheme. Pembrolizumab was given at
the request of the treating physician as the iCare Medical
Advisory Committee had previously approved such use.
Oncologists were invited to provide retrospective data of
patients with mesothelioma who were treated with
pembrolizumab between August 2015 and July 2019. This
study was approved by the Sydney Local Health District
Human Research Ethics Committee of the Concord
Repatriation General Hospital (HREC/16/CRGH/177)
with a waiver of informed consent.Baseline Variables
Clinical and pathologic data were collected retro-
spectively from medical records of the participating
cancer centers using a predefined template. Fields
included age, sex, histologic subtype, baseline Eastern
Cooperative Oncology Group (ECOG) performance status
(PS), location of mesothelioma, smoking history,
extrapleural pneumonectomy, line of pembrolizumab
therapy, and cycles of pembrolizumab and dexametha-
sone prepembrolizumab (defined as patients who were
already receiving dexamethasone medication at the time
of commencement of pembrolizumab treatment). Dif-
ferential blood counts and prognostic inflammatory
markers were also collected, as reported previously,14
including neutrophil-to-lymphocyte ratio (NLR),
defined as the absolute neutrophil count divided by the
absolute lymphocyte count. An NLR of five or greater
was considered to be elevated.14Clinical Outcomes
The following clinical information was collected and
measured: (1) response to pembrolizumab, assessed as
per the standard modified Response Evaluation Criteria
in Solid Tumors (RECIST) criteria for mesothelioma; (2)
toxicity according to Common Terminology Criteria for
Adverse Events version 4.03; (3) OS from the start date
of pembrolizumab treatment until the date of death from
any cause; and (4) PFS from the start date of pem-
brolizumab treatment until the date of disease progres-
sion or date of death from any cause (whichever
occurred first). Patients were censored at the last follow-up date if they were still alive at the end of the study.
Responses were obtained from radiologic imaging and
reported by the operating oncologist. ORR was defined
as the number of patients with complete response (CR)
or partial response (PR) as a percentage of the total
number of patients. Disease control rate (DCR) was
defined as the number of patients with CR, PR, or stable
disease as a percentage of the total number of patients.Immunohistochemistry
All available archival formalin-fixed paraffin-
embedded tumor samples were collected and evaluated in
a central location (Royal Prince Alfred Hospital, Sydney,
Australia) by an experienced thoracic pathologist who
was blinded to the clinical outcome data. Immunohisto-
chemistry was performed on a Bond III Autostainer
PTLink using the Bond Polymer Refine Detection Kit
(Leica Biosystems Nussloch GmbH, Nußloch, Germany),
with a high-pH target retrieval buffer (Leica Biosystems),
as per manufacturer’s instructions. Formalin-fixed
paraffin-embedded tumor samples were stained for PD-
L1 (E1L3N clone, 1:75 dilution; XP Rabbit Monoclonal
Antibody, Cell Signaling Technology, Danvers, MA), BAP1
(C-4 clone, 1:100 dilution; Santa Cruz Mouse Monoclonal
Antibody, Dallas, TX), and TILs in the intratumoral
component and the tumor-associated stroma (CD3-
positive [CD3þ]; LN10 clone, 1:200 dilution; Novocastra,
Newcastle Upon Tyne, United Kingdom).
PD-L1 expression was assessed by the tumor pro-
portion score (TPS), defined as the percentage of tumor
cells with any membranous staining of any intensity (0%–
100%). PD-L1 expression was considered positive if TPS
was greater than or equal to 1%. BAP1 expression was
considered as positive or negative based on nuclear
staining, with negative indicating abnormal loss of protein
expression. CD3þ TILs were assessed in the intratumoral
component and in the tumor-associated stroma.Statistical Analysis
Survival curves and survival proportions were esti-
mated using the method of Kaplan-Meier and compared
using a log-rank test. The median follow-up time was
estimated using the reverse Kaplan-Meier method.
Scores for CD3þ TILs and blood counts were dichoto-
mized on the basis of the distributions to ensure suffi-
cient numbers in each group. A cutoff of greater than or
equal to 5% was used to categorize CD3þ TILs in the
tumor and stroma. Cox proportional hazards models
were used to investigate the association of each marker
with OS and PFS. Factors with a known or statistically
significant prognostic association were then entered into
a multivariable Cox regression model to determine their
independent effect.
Table 2. Baseline Demographics for the Study of Patients, N (%)
Variable


























Pembrolizumab line of therapy
First line 4 4
Second line 63 64
Third line 21 21
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Table 2. Continued
Variable
All patients (N ¼ 98)
N %









Low (<0.02) 16 16
Normal (0.02–0.5) 70 71
High (>0.5) 5 5
Missing 7 7
Albumin count, g/liter
Low (<26) 6 6
Normal (26–42) 78 80
High (>42) 8 8
Missing 6 6
Biomarkers
















Note: BAP1, BRCA1 associated protein-1; irAE, immune-related adverse event; TIL, tumor-infiltrating lymphocyte; ECOG PS, Eastern Cooperative Oncology
Group performance status; EPP, extrapleural pneumonectomy; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed cell death-ligand 1; TPS, tumor
proportion score.
6 Ahmadzada et al JTO Clinical and Research Reports Vol. 1 No. 4The relationship between ORR and significant clinical
factors and biomarkers was analyzed using logistic
regression. The OR with the corresponding 95% confi-
dence interval (CI) was used to assess the relationship.
For variables with insufficient numbers to conduct lo-
gistic regression, Fisher’s exact test was applied to
determine the relationship. A p value of 0.05 or less was
considered statistically significant. Stata SE 14.2 soft-
ware was used for the statistical analysis.Results
Patient Demographics and Outcomes
A total of 98 patients were included in the study, and
76 tumor samples were available for analysis. At the endof the study period, 27 patients were alive. Baseline
characteristics are provided in Table 2. The median age
was 70 years (range, 46–91 y). Most patients were men
(92%) diagnosed with MPM (97%) of the epithelioid
subtype (76%), had ECOG PS 0 to 1 (78%), and did not
undergo extrapleural pneumonectomy (91%). Most pa-
tients received previous treatments, predominantly
combination chemotherapy, before commencing pem-
brolizumab (Supplementary Table 1). Four patients
(4%) received pembrolizumab as first-line treatment as
they were unfit for chemotherapy for a variety of rea-
sons. A total of 63 patients (64%) received pem-
brolizumab as second-line treatment and 31 patients
(32%) as third-line or later. None of the patients were
selected based on biomarker expression. The dose of
Figure 1. Kaplan-Meier curves for (A) PFS in the entire cohort and according to (B) ECOG PS, (C) baseline platelet count, (D)
PD-L1 expression, and (E) histologic subtype. ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1,
programmed cell death-ligand 1; PFS, progression-free survival.
November 2020 Evaluation of Pembrolizumab in Mesothelioma 7
Table 3. ORR According to Key Factors
Variable CR þ PR, n (%) SD þ PD, n (%) OR (95% CI) p Value
Total cohort 18 (18)
(1 CRþ17 PR)
79 (81)
(37 SD þ 42 PD)
— —
ECOG PS, n ¼ 95
0 8 (38) 13 (62) 0.25(0.08–0.77) 0.02
1 10 (14) 64 (86)
Dexamethasone prepembrolizumab, n ¼ 96
No 17 (20) 68 (80) 0.40 (0.48–3.34) 0.40
Yes 1 (9) 10 (91)
Baseline platelet count ( 109/liter), n ¼ 92
400 13 (20) 51 (80) 0.49 (0.13–1.88) 0.30
>400 3 (11) 24 (89)
PD-L1 expression, %, n ¼ 76
<1 5 (11) 40 (89) 2.33 (0.67–8.18) 0.19
1 7 (23) 24 (77)
BAP1 expression n ¼ 75
Loss 7 (20) 28 (80) 0.57 (0.16–2.00) 0.38
Retained 5 (13) 35 (87)
CD3 tumor, %, n ¼ 76
<5 2 (5) 38 (95) — <0.01a
5 10 (28) 26 (72)
CD3 stroma, %, n ¼ 71
<5 0 7 (100) — 0.26a
5 12 (19) 52 (81)
Note: aFisher’s exact test applied.
BAP1, BRCA1 associated protein-1; CI, confidence interval; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR,
overall response rate; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease.
8 Ahmadzada et al JTO Clinical and Research Reports Vol. 1 No. 4pembrolizumab was 200 mg (flat dose) administered
every 3 weeks for 73% of patients and 2 mg/kg (weight-
based) every 3 weeks for 27% of patients. The number
of cycles of pembrolizumab varied from 1 to 35, with a
median of six cycles (interquartile range, 4–12). At the
commencement of pembrolizumab treatment, 12 pa-
tients (12%) were on dexamethasone medication, which
was given to boost energy, stimulate appetite, or palliate
symptoms.
In the full cohort, the ORR was 18% (95% CI: 12%–
28%), which included one CR and 17 PR. The DCR was
56% (95% CI: 47%–66%), which included 37 stable
diseases. For patients who had a PR or CR (n ¼ 18), the
median duration of treatment was 12.9 months (inter-
quartile range: 10.4–18.9 mo), defined as the time from
date of pembrolizumab treatment to date of disease
progression, date of death, or date of censoring, which-
ever occurred first. Three patients had pseudoprog-
ression, defined as a patient who seemed to progress
initially on imaging (RECIST progression), followed by a
response. Two of these patients were reported previ-
ously.15 Response in one patient was not assessable as
the patient passed away before imaging. A total of 13
patients received other treatments post-pembrolizumab,
such as combination chemotherapy with or without
bevacizumab (Supplementary Table 2). Of these, two
patients (15%) had PR. Overall, the median PFS was 4.8months (95% CI: 3.6–6.2 mo) (Fig. 1A), and the median
OS was 9.5 months (95% CI: 6.6–13.7 mo) (Fig. 2A). The
median follow-up was 21.3 months (95% CI: 17.9–22.9
mo), and the OS rate at 12 and 24 months was 41% and
21%, respectively.
Immune-related adverse events (irAEs) of any grade
occurred in 26 patients (27%), with eight patients (8%)
experiencing grade 3 or higher irAEs. These included
pneumonitis (four cases, 4%), nephritis (one case, 1%),
scleroderma (one case, 1%), and hepatitis (one case,
1%), with one patient experiencing grade 3 myasthenia
gravis (1%) and diarrhea or colitis (1%). Other irAEs
included grade 1 to 2 rash or pruritus (six cases, 6%),
grade 2 pneumonitis (one case, 1%), grade 1 to 2 diar-
rhea or colitis (three cases, 3%), grade 2 nephritis (one
case, 1%), grade 1 arthralgia (two cases, 2%), grade 1
dry mouth (one case 1%), grade 1 to 2 hyperthyroidism
(three cases, 3%), grade 1 thyroid function test abnor-
malities (one case, 1%) and grade 2 synovitis (one case,
1%) (Supplementary Table 3).Biomarkers: PD-L1 TPS Score, BAP1, and TILs
Examples of cytoplasmic staining of each biomarker
are illustrated in Figure 1. BAP1 score was not assess-
able in one patient, and CD3þ TILs in the stroma was not
assessable in five patients. PD-L1 TPS of greater than or
Figure 2. Kaplan-Meier curves for (A) overall survival in the entire cohort and according to (B) baseline platelet count, (C)
dexamethasone prepembrolizumab, and (D) histologic subtype.
November 2020 Evaluation of Pembrolizumab in Mesothelioma 9equal to 1% was observed in 31 of 76 patients (41%),
and loss of nuclear BAP1 was observed in 35 of 75 pa-
tients (47%). CD3þ TILs (5%) was observed in 36 of
76 patients (47%) within the tumor and in 64 of 71
patients (90%) within the stroma.Factors Associated With Response, OS, and PFS
The odds of a response to pembrolizumab were
higher for patients with baseline ECOG PS 0 (OR for
ECOG 1: 0.25; 95% CI: 0.08–0.77; p ¼ 0.02). In addi-
tion, there was an association between ORR and CD3þ
TILs (5%) within the tumor (ORR: 28% versus 5%; p <
0.01) but not in the stroma (p ¼ 0.26). PD-L1 expression
and BAP1 loss were not significantly associated withORR (Table 3), although the ORR was numerically higher
for patients with PD-L1 TPS score of greater than or
equal to 1% (23% versus 11%) and patients who had
BAP1 loss (20% versus 13%).
In univariate analysis (Supplementary Table 4), fac-
tors predictive of better PFS included ECOG PS 0 (me-
dian PFS: 12 mo versus 4 mo, p < 0.01), baseline platelet
count of less than or equal to 400  109/liter (median
OS: 6 mo versus 2 mo, p ¼ 0.01) and CD3þ TILs (5%)
in the tumor (median PFS: 6 mo versus 4 mo, p ¼ 0.02).
In the multivariable analysis (Fig. 1), factors indepen-
dently predictive of PFS included ECOG PS greater than
or equal to 1 (hazard ratio [HR] ¼ 3.85; 95% CI: 1.54–
9.64; p < 0.01) (Fig. 1B), baseline platelet count of
greater than 400  109/liter (HR¼ 1.93; 95% CI: 1.01–
Figure 3. Examples of MPM tumor sections stained for PD-L1, BAP1, and CD3-positive TILs in the tumor and stroma. MPM,
malignant pleural mesothelioma; TIL, tumor-infiltrating lymphocyte; PD-L1, programmed death-ligand 1.
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than or equal to 1% (HR: 0.31; 95% CI: 0.52–0.63; p <
0.01) (Fig. 1D). The presence of CD3þ TILs (5%) in the
tumor was not independently predictive of PFS (p ¼
0.40).
Factors predictive of longer OS in our univariate
analysis included ECOG PS 0 (median OS: 18 mo versus 8
mo, p ¼ 0.01), lack of dexamethasone prepem-
brolizumab (median OS: 10 mo versus 3 mo, p < 0.01)
and baseline platelet count of less than or equal to 400 
109/liter (median OS: 10 mo versus 4 mo, p < 0.01)
(Supplementary Table 5). In the multivariable analysis
(Fig. 2), factors that were independently predictive of OS
included baseline platelet count of greater than 400 
109/liter (HR: 2.37; 95% CI: 1.21–4.63; p ¼ 0.01) (Fig.
2B) and dexamethasone prepembrolizumab (HR: 4.37;
95% CI: 1.45–13.13; p ¼ 0.01) (Fig. 2C). Neither BAP1
loss nor CD3þ TILs (5%) in the stroma were predictive
of PFS nor OS. Histologic subtype was not associated
with a response, nor with PFS and OS (Figs. 1E and 2D).
This may be because of the uneven distribution of data,
with a small number of patients having nonepithelioid
subtype (n ¼ 16) and most patients having epithelioid
subtype (n ¼ 74).Discussion
We presented the outcomes to pembrolizumab from a
large real-world cohort of patients with mesothelioma
and explored predictive factors that correlated with
outcome. We observed an ORR of 18%, DCR of 56%,
median PFS of 4.8 months, and median OS of 9.5 months.
Our outcomes were comparable to similar real-world
data recently reported by Metaxas et al.16 In addition,
our data exhibited that pembrolizumab was well
tolerated, given that only eight patients (8%) experienced
grade 3 or higher irAEs, which were similar to those re-
ported in clinical trials (Supplementary Table 3).7,12,16-23
Our study suggests that the use of pembrolizumab mon-
otherapy in malignant mesothelioma patients is safe, with
activity in line with the available literature.
It is clear from our study that not all patients benefit
from this immunotherapeutic approach. This observa-
tion is consistent with the results from the phase 3
prospective randomized PROMISE-Meso trial,23 which
compared pembrolizumab with chemotherapy with
either single-agent gemcitabine or vinorelbine in the
second-line setting. Although pembrolizumab treatment
led to a superior ORR, it did not provide a survival
advantage in terms of either PFS or OS compared with
chemotherapy despite correcting for crossover.23 Given
the somewhat disappointing results of the PROMISE-
Meso trial, two broad strategies have been suggested
to improve patient outcomes. The first is to combine PD-1or PD-L1 inhibition with other treatments with the hope
of potentiating efficacy. Promising results have emerged
in mesothelioma and other tumor settings by combining
immunotherapy with chemotherapy or through com-
bined targeting of different immune checkpoint in-
hibitors (ICIs).24 In the DREAM study, a phase 2 single-
arm trial (n ¼ 54), durvalumab (PD-L1 antibody) was
combined with cisplatin plus pemetrexed as first-line
treatment in patients with MPM. The objective tumor
response was 48% according to modified RECIST and
50% according to immune RECIST,21 which is one of the
highest reported so far. In the MAPS2 study, combined
targeting of PD-1 and CTLA-4 also exhibited a high
response rate (30%) and comparable median OS and PFS
(Table 1).22 Similar ORRs were observed in the
INITIATE20 and NIBIT-MESO-118 trials, which combined
PD-1 and PD-L1 blockade, respectively, with CTLA-4
inhibitors, with low and manageable toxicity. These re-
sults suggest that combination immunotherapy or che-
moimmunotherapy may be viable treatment options for
patients with mesothelioma.
The second strategy to improve patient outcomes is
to identify those that are likely to benefit from immu-
notherapy alone. Predictive biomarkers of PD-1 or PD-L1
inhibition in malignant mesothelioma have not been
clearly defined, and our study aimed to explore this
vexing question. In MPM, PD-L1 expression has been
suggested as an adverse prognostic biomarker and
associated with the nonepithelioid subtype.25 However,
response to pembrolizumab has been observed in pa-
tients with MPM regardless of PD-L1 status, and no clear
correlation has yet been found between PD-L1 expres-
sion and response to immunotherapy using PD-1 or PD-
L1 checkpoint blockade.5,12,17-19,22,26,27 Nevertheless, it
seems that a higher proportion of patients with PD-L1
TPS score of greater than or equal to 1% respond to
pembrolizumab and have prolonged PFS and OS,
compared with those that do not stain for PD-L1. This
was observed in our study and in the MERIT study
involving patients treated with nivolumab (PD-1 anti-
body).28 Similarly, in the JAVELIN study involving pa-
tients treated with avelumab (PD-L1 antibody), higher
ORR and prolonged PFS and OS was observed in those
with PD-L1 TPS score of greater than or equal to 5%.29
In a retrospective cohort of Metaxas et al.,16 PD-L1
expression was significantly associated with response
in MPM, with ORRs of 11%, 42%, and 44% for PD-L1
expressions of less than 5%, 5% to 49%, and greater
than or equal to 50%, respectively. In other studies, PD-
L1 expression was found to be a predictive biomarker of
ICIs in NSCLC and bladder, cervical, and gastric or
gastroesophageal junction cancers.30 However, the
methodologies across clinical trials are inconsistent,
including the use of variable PD-L1 antibodies, assays,
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(PD-L1 expression measured either on tumor cells or
tumor-infiltrating immune cells, or both).30 Overall, the
role of PD-L1 as a predictive biomarker for immuno-
therapy still remains unclear, and larger prospective
studies are required to verify its predictive power.
Emerging evidence suggests that TILs may have
predictive value for anti–PD-L1 or PD-1 therapy. In a
small-scale study, an association was found between the
ratio of CD8-positive (CD8þ)/CD4-positive TILs and
response to anti–PD-1 treatment in NSCLC and meta-
static melanoma.31 Furthermore, in the KEYNOTE-119
trial, high TILs were significantly associated with bet-
ter clinical outcomes from pembrolizumab, but not from
chemotherapy, in metastatic triple-negative breast can-
cer.32 Similarly, in our study, TILs were associated with
response to pembrolizumab. To understand this rela-
tionship, it is important to characterize the tumor
microenvironment. Clinical responses to anti–PD-L1 or
PD-1 therapy generally occur in patients with inflamed
tumors.33 An inflamed phenotype suggests that there is a
preexisting antitumor activity in the tumor microenvi-
ronment.33 We previously reported that most MPM pa-
tients had an inflamed tumor irrespective of PD-L1
status.34 It is possible that in an inflamed tumor micro-
environment, TILs are restimulated during immuno-
therapy, triggering a response. However, not all patients
with TILs in the tumor respond, suggesting that
other factors are involved in the highly heterogenous
MPM tumor microenvironment. Although we only
investigated CD3þ TILs in our study, other subtypes of
TILs contribute to an immune response, such as CD4-
positive and CD8þ T-lymphocytes, Foxp3-positive reg-
ulatory T-cells, and CD20-positive B-lymphocytes.33,35
Therefore, combining different lymphocyte subsets and
multiple biomarkers could help better determine the
importance of TILs as a predictive biomarker for
immunotherapy.
Markers such as NLR and differential blood counts
have exhibited prognostic value in MPM.14,36-38 However,
they have not been widely investigated in clinical trials,
and it is not known whether they can predict response to
immunotherapy. In the phase 2 NivoMes trial, lympho-
cytes, lactate dehydrogenase, C-reactive protein, and NLR
were investigated for their predictive value in addition to
PD-L1. Neither of these markers correlated with response
to nivolumab nor with progressive disease; however, an
increase in NLR from baseline to week 6 was significantly
associated with the nonresponse.12 In our study, differ-
ential blood counts did not predict outcomes from pem-
brolizumab (Supplementary Tables 4 and 5), with the
exception of elevated baseline platelet count (>400 
109/liter), which was an independent predictor of lower
OS and PFS. This is consistent with previous observations,as platelets are known to release a large number of
proangiogenic factors, for example, VEGF,37 which is an
adverse prognostic factor and predicts a worse outcome
in MPM.39
There are scarce data regarding other predictive
biomarkers for immunotherapy. We investigated the
predictive role of BAP1, a tumor suppressor gene.7,40,41
BAP1 is involved in regulating transcription by deubi-
quitinating target histones.40,41 Loss of BAP1 has been
associated with aberrant activity of enhancer of zeste
homolog 2, which is involved in gene expression and
histone methylation.40,41 Recently, BAP1 loss was asso-
ciated with an inflamed tumor microenvironment in
peritoneal mesothelioma42 and uveal melanoma,43 sug-
gesting that it could be a candidate predictive biomarker
for immunotherapy. Although we did not observe an
association between BAP1 loss and clinical outcomes to
pembrolizumab treatment in our study, our results may
have been limited by our small sample size. Larger
studies are encouraged to further explore the role of
BAP1 as a predictive biomarker.
We found that other clinical factors, such as the use of
corticosteroids and onset of irAEs, may also affect out-
comes to pembrolizumab. Corticosteroids are typically
used to manage the adverse effects of chemotherapy,
such as nausea, pain, vomiting, and rash.12,44 They are
also often prescribed in patients with advanced meso-
thelioma for symptom palliation. Baseline corticosteroid
use has been associated with poorer outcomes in pa-
tients with NSCLC treated with ICIs and is considered a
surrogate for poor PS.45-47 However, there is also evi-
dence to suggest that corticosteroids may reduce the
efficacy of ICIs. In a preclinical mesothelioma mouse
model, the addition of corticosteroids reduced the
response to gemcitabine chemotherapy plus anti–CTLA-
4 and anti–PD-1 ICIs.44 Dexamethasone was also re-
ported to reduce the effectiveness of ICIs through sup-
pression of interleukin-2 and potentially blunt the
proliferative burst of CD8þ T-lymphocytes.47 In our
study, the significant association of dexamethasone with
the shorter OS, but not PFS, suggests it could be a sur-
rogate for poorer PS. However, it remains unclear
whether dexamethasone reduced the efficacy of pem-
brolizumab or had an impact on ECOG PS, given that
ECOG PS was measured at the commencement of pem-
brolizumab treatment and not at the commencement of
dexamethasone medication.
The onset of irAEs may also affect outcomes to
pembrolizumab; however, larger studies are needed to
exhibit its effect. IrAEs can represent bystander effects
from activated T-cells; therefore, patients responding to
immunotherapy would have a higher likelihood of tox-
icities.48 This theory has encouraged studies to investi-
gate the onset of irAEs as a predictive biomarker of
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cancer (reviewed in Das and Johnson48). Similar studies
are encouraged to further investigate their role in the
efficacy of immunotherapy in mesothelioma.
Finally, we reported that the functional status of a
patient is a significant factor in their response to treat-
ment. Although it is difficult to infer a causative rela-
tionship, it is not surprising that patients with better
functional status would perform best after treatment.
ECOG score of greater than 0 is considered to be an in-
dependent predictor of poor outcome,49 and we found
that patients with ECOG score of 0 have longer survival
and better response to pembrolizumab than patients
with ECOG score of 1 or higher. It is important to note
that our real-world study included a small number of
patients with an ECOG score of greater than 1. Although
this did not have an effect on the outcomes in our study,
it may have contributed to our relatively lower survival
outcomes than clinical trials, which selected patients
with an ECOG score of 0 to 1 (Table 1).
The retrospective design and size of our study are its
main limitations. It did not allow us to select for pre-
defined patient populations or standardize treatment
regimens. Although data from a real-world population
can provide a more practical perspective of pem-
brolizumab toxicity and efficacy, larger prospective trials
are needed to confirm the benefits of immunotherapy
compared with chemotherapy. Further information will
be known after the results of CheckMate 743
(NCT02899299), a large-scale, randomized phase 3 trial,
which compared combination immunotherapy versus
combination chemotherapy as first-line treatment in
MPM.50 Interim unpublished results revealed promising
outcomes, with combination immunotherapy exhibiting
significant improvements in OS compared with combi-
nation chemotherapy.51
Summary and Conclusion
We have presented real-world data on the safety and
efficacy of pembrolizumab in mesothelioma from the
largest patient cohort analyzed to date. We found that
single-agent pembrolizumab is well tolerated by patients
and is effective in a small proportion. Although the
immuno-oncology field in mesothelioma is moving to-
ward the combination strategy with chemotherapy, there
still remains a strong clinical desire to better select pa-
tients for whom single-agent immunotherapy is the
optimal choice. We illustrated that traditional PS
assessment remains the most robust predictor for pa-
tient outcome with an ECOG status of 0 associated with
better ORR and PFS. Other factors such as the lack of
pretreatment dexamethasone, nonelevated absolute
platelet count, and PD-L1 expression may predict for
longer survival, whereas TILs in the tumor may helpselect patients that are likely to respond to pem-
brolizumab. These factors should be evaluated in a larger
cohort and considered when designing protocols for
prospective clinical trials. Larger studies are also
required to verify the predictive value of PD-L1 and
BAP1 for immunotherapy.
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